The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Harnessing the immune system to improve cancer therapy
Open accessAbstract
Cancer immunotherapy uses the immune system and its components to mount an anti-tumor response. During the last decade, it has evolved from a promising therapy option to a robust clinical reality. Many immunotherapeutic modalities are already approved by the Food and Drug Administration (FDA) for treating cancer patients and many others are in the pipeline for approval as standalone or combinatorial therapeutic interventions, several also combined with standard treatments in clinical studies. The two main axes of cancer immunotherapeutics refer to passive and active treatments. Prominent examples of passive immunotherapy include administration of monoclonal antibodies and cytokines and adoptive cell transfer of ex vivo "educated" immune cells. Active immunotherapy refers, among others, to anti-cancer vaccines [peptide, dendritic cell (DC)-based and allogeneic whole cell vaccines], immune checkpoint inhibitors and oncolytic viruses, whereas new approaches that can further enhance anti-cancer immune responses are also widely explored. Herein, we present the most popular cancer immunotherapy approaches and discuss their clinical relevance referring to data acquired from clinical trials. To date, clinical experience and efficacy suggest that combining more than one immunotherapy interventions, in conjunction with other treatment options like chemotherapy, radiotherapy and targeted or epigenetic therapy, should guide the way to cancer cure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,336
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Weber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Andtbacka, R. H. I., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K. A., Spitler, L. E., Puzanov, I., Agarwala, S. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3377 · Cited by 2,634
IDENTIFICATION OF A NOVEL CELL TYPE IN PERIPHERAL LYMPHOID ORGANS OF MICE
Steinman, R. M., & Cohn, Z. A. (1973) · The Journal of Experimental Medicine · doi:10.1084/jem.137.5.1142 · Cited by 2,424
Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
Albert, M. L., Sauter, B., & Bhardwaj, N. (1998) · Nature · doi:10.1038/32183 · Cited by 2,349
The PD‐1 pathway in tolerance and autoimmunity
Francisco, L. M., Sage, P. T., & Sharpe, A. H. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00923.x · Cited by 2,300
Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,140
Cancer immunotherapy via dendritic cells
Palucka, K., & Banchereau, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3258 · Cited by 2,049
Complement and its role in innate and adaptive immune responses
Dunkelberger, J. R., & Song, W.-C. (2010) · Cell Research · doi:10.1038/cr.2009.139 · Cited by 1,932
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Sharpe, A. H., & Freeman, G. J. (2002) · Nature Reviews Immunology · doi:10.1038/nri727 · Cited by 1,712
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,658
Gross, G., Waks, T., & Eshhar, Z. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.10024 · Cited by 1,590
Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00083-2 · Cited by 1,572
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512
Adaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,436
Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,418
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
Li, S., Schmitz, K. R., Jeffrey, P. D., Wiltzius, J. J. W., Kussie, P., & Ferguson, K. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.003 · Cited by 1,118
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Motzer, R. J., Rini, B. I., McDermott, D. F., Redman, B. G., Kuzel, T. M., Harrison, M. R., Vaishampayan, U. N., Drabkin, H. A., George, S., Logan, T. F., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0703 · Cited by 1,074
Fcγ Receptors: Old Friends and New Family Members
Nimmerjahn, F., & Ravetch, J. V. (2006) · Immunity · doi:10.1016/j.immuni.2005.11.010 · Cited by 1,072
Gattinoni, L., Finkelstein, S. E., Klebanoff, C. A., Antony, P. A., Palmer, D. C., Spiess, P. J., Hwang, L. N., Yu, Z., Wrzesinski, C., Heimann, D. M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050732 · Cited by 1,061
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
Schwartzentruber, D. J., Lawson, D. H., Richards, J. M., Conry, R. M., Miller, D. M., Treisman, J., Gailani, F., Riley, L., Conlon, K., Pockaj, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012863 · Cited by 911
Carpenito, C., Milone, M. C., Hassan, R., Simonet, J. C., Lakhal, M., Suhoski, M. M., Varela-Rohena, A., Haines, K. M., Heitjan, D. F., Albelda, S. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813101106 · Cited by 888
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross, P. F., Beitz, J. G., Chen, G., Chen, X., Duffy, E. J., Kieffer, L. V., Roy, S., Sridhara, R. N., Rahman, A., Williams, G., et al. (2001) · PubMed · Cited by 855
Leonard, J. P., Sherman, M. L., Fisher, G. L., Buchanan, L. J., Larsen, G., Atkins, M. B., Sosman, J. A., Dutcher, J. P., Vogelzang, N. J., & Ryan, J. L. (1997) · PubMed · Cited by 820
IDENTIFICATION OF A NOVEL CELL TYPE IN PERIPHERAL LYMPHOID ORGANS OF MICE
Steinman, R. M., & Cohn, Z. A. (1974) · The Journal of Experimental Medicine · doi:10.1084/jem.139.2.380 · Cited by 814
Patnaik, A., Kang, S. P., Rasco, D., Papadopoulos, K. P., Elassaiss-Schaap, J., Beeram, M., Drengler, R., Chen, C., Smith, L., Espino, G., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2607 · Cited by 807
Liu, B. L., Robinson, M., Han, Z.-Q., Branston, R. H., English, C., Reay, P., McGrath, Y., Thomas, S. K., Thornton, M., Bullock, P., et al. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301885 · Cited by 803
Synthetic Nanoparticles for Vaccines and Immunotherapy
Irvine, D. J., Hanson, M. C., Rakhra, K., & Tokatlian, T. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00109 · Cited by 763
Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma
Daud, A. I., DeConti, R. C., Andrews, S., Urbas, P., Riker, A. I., Sondak, V. K., Munster, P. N., Sullivan, D. M., Ugen, K. E., Messina, J. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.6794 · Cited by 701
Remote control of therapeutic T cells through a small molecule–gated chimeric receptor
Wu, C.-Y., Roybal, K. T., Puchner, E. M., Onuffer, J., & Lim, W. A. (2015) · Science · doi:10.1126/science.aab4077 · Cited by 687
Pegram, H. J., Lee, J. C., Hayman, E. G., Imperato, G. H., Tedder, T. F., Sadelain, M., & Brentjens, R. J. (2012) · Blood · doi:10.1182/blood-2011-12-400044 · Cited by 678
Chmielewski, M., Kopecky, C., Hombach, A. A., & Abken, H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0103 · Cited by 562
Di Stasi, A., De Angelis, B., Rooney, C. M., Zhang, L., Mahendravada, A., Foster, A. E., Heslop, H. E., Brenner, M. K., Dotti, G., & Savoldo, B. (2009) · Blood · doi:10.1182/blood-2009-03-209650 · Cited by 533
Lundin, J., Kimby, E., Björkholm, M., Broliden, P.-A., Celsing, F., Hjalmar, V., Möllgård, L., Rebello, P., Hale, G., Waldmann, H., et al. (2002) · Blood · doi:10.1182/blood-2002-01-0159 · Cited by 497
Overview of interleukin-2 function, production and clinical applications
GAFFEN, S., & LIU, K. (2004) · Cytokine · doi:10.1016/j.cyto.2004.06.010 · Cited by 431
NY‐ESO‐1: Review of an Immunogenic Tumor Antigen
(2006) · Advances in Cancer Research · doi:10.1016/s0065-230x(06)95001-5 · Cited by 405
Bour‐Jordan, H., Esensten, J. H., Martinez‐Llordella, M., Penaranda, C., Stumpf, M., & Bluestone, J. A. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01011.x · Cited by 391
Prospects for gene-engineered T cell immunotherapy for solid cancers
Klebanoff, C. A., Rosenberg, S. A., & Restifo, N. P. (2016) · Nature Medicine · doi:10.1038/nm.4015 · Cited by 365
Interferon-alpha in tumor immunity and immunotherapy
Belardelli, F., Ferrantini, M., Proietti, E., & Kirkwood, J. M. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00022-3 · Cited by 337
Urbanska, K., Lanitis, E., Poussin, M., Lynn, R. C., Gavin, B. P., Kelderman, S., Yu, J., Scholler, N., & Powell, D. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3890 · Cited by 322
Zhang, L., Kerkar, S. P., Yu, Z., Zheng, Z., Yang, S., Restifo, N. P., Rosenberg, S. A., & Morgan, R. A. (2011) · Molecular Therapy · doi:10.1038/mt.2010.313 · Cited by 293
Rech, A. J., & Vonderheide, R. H. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04939.x · Cited by 289
Rook, A. H., Wood, G. S., Yoo, E. K., Elenitsas, R., Kao, D. M. F., Sherman, M. L., Witmer, W. K., Rockwell, K. A., Shane, R. B., Lessin, S. R., et al. (1999) · Blood · doi:10.1182/blood.v94.3.902.415k23_902_908 · Cited by 277
Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies
Tamada, K., Geng, D., Sakoda, Y., Bansal, N., Srivastava, R., Li, Z., & Davila, E. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1449 · Cited by 259
Combinations of Immunotherapy and Radiation in Cancer Therapy
Vatner, R. E., Cooper, B. T., Vanpouille-Box, C., Demaria, S., & Formenti, S. C. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00325 · Cited by 240
Systemic Delivery of Oncolytic Viruses: Hopes and Hurdles
Ferguson, M. S., Lemoine, N. R., & Wang, Y. (2012) · Advances in Virology · doi:10.1155/2012/805629 · Cited by 231
de Gruijl, T. D., van den Eertwegh, A. J. M., Pinedo, H. M., & Scheper, R. J. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0536-z · Cited by 201
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade
Buchbinder, E., & Hodi, F. S. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80012 · Cited by 178
GM-CSF-secreting melanoma vaccines
Dranoff, G. (2003) · Oncogene · doi:10.1038/sj.onc.1206459 · Cited by 166
Inhibitory receptors as targets for cancer immunotherapy
Turnis, M. E., Andrews, L. P., & Vignali, D. A. A. (2015) · European Journal of Immunology · doi:10.1002/eji.201344413 · Cited by 165
Peptide-Based Treatment: A Promising Cancer Therapy
Xiao, Y.-F., Jie, M.-M., Li, B.-S., Hu, C.-J., Xie, R., Tang, B., & Yang, S.-M. (2015) · Journal of Immunology Research · doi:10.1155/2015/761820 · Cited by 163
The immunocytokine NHS-IL12 as a potential cancer therapeutic
Fallon, J., Tighe, R., Kradjian, G., Guzman, W., Bernhardt, A., Neuteboom, B., Lan, Y., Sabzevari, H., Schlom, J., & Greiner, J. W. (2014) · Oncotarget · doi:10.18632/oncotarget.1853 · Cited by 160
Racila, E. V., Link, B. K., Weng, W., Witzig, T. E., Ansell, S. M., Maurer, M. J., Huang, J., Dahle, C. E., Halwani, A. S., Levy, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0745 · Cited by 159
Lin, A. Y., Almeida, J. P. M., Bear, A. S., Liu, N., Luo, L., Foster, A. E., & Drezek, R. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063550 · Cited by 155
Gil, M., Komorowski, M. P., Seshadri, M., Rokita, H., McGray, A. R., Opyrchal, M., Odunsi, K. O., & Kozbor, D. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400201 · Cited by 153
Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy
Rojas, J. J., Sampath, P., Hou, W., & Thorne, S. H. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2009 · Cited by 144
Differential Effects of IL-12 on Tregs and Non-Treg T Cells: Roles of IFN-γ, IL-2 and IL-2R
Zhao, J., Zhao, J., & Perlman, S. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046241 · Cited by 142
Le, D. T., Pardoll, D. M., & Jaffee, E. M. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eb33d7 · Cited by 141
Qiao, J., Kottke, T. J., Willmon, C. L., Galivo, F., Wongthida, P., Díaz, R. M., Thompson, J., Ryno, P. K., Barber, G. N., Chester, J. D., et al. (2007) · Nature Medicine · doi:10.1038/nm1681 · Cited by 141
Cytokine Induced Killer Cells as Promising Immunotherapy for Solid Tumors
Sangiolo, D. (2011) · Journal of Cancer · doi:10.7150/jca.2.363 · Cited by 138
Kilinc, M. O., Aulakh, K. S., Nair, R. E., Jones, S. A., Alard, P., Kosiewicz, M. M., & Egilmez, N. K. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.6962 · Cited by 136
Trial Watch: Peptide-based anticancer vaccines
Pol, J. G., Bloy, N., Buqué, A., Eggermont, A. M. M., Cremer, I., Sautès‐Fridman, C., Galon, J., Tartour, É., Zitvogel, L., Kroemer, G., et al. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.974411 · Cited by 129
Cancer Immunotherapy via Dendritic Cells
Palucka, K., & Banchereau, J. (2013) · Springer eBooks · doi:10.1007/978-3-7091-1300-4_4 · Cited by 128
Parente‐Pereira, A. C., Burnet, J., Ellison, D. H., Foster, J., Davies, D. M., van der Stegen, S. J. C., Papa, S., Chiapero-Stanke, L., Wilkie, S., Mather, S. J., et al. (2011) · Journal of Clinical Immunology · doi:10.1007/s10875-011-9532-8 · Cited by 118
PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses
Ma, W., Chen, Kaushal, McElroy, Zhang, Y., Ozkan, C. S., Bouvet, Minev, Kruse, F., Grotjahn, et al. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s29506 · Cited by 116
Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma
Little, R. F., Pluda, J. M., Wyvill, K. M., Rodriguez-Chavez, I. R., Tosato, G., Catanzaro, A. T., Steinberg, S. M., & Yarchoan, R. (2006) · Blood · doi:10.1182/blood-2005-11-4455 · Cited by 115
Duewell, P., Kisser, U., Heckelsmiller, K., Hoves, S., Stoitzner, P., Koernig, S., Morelli, A. B., Clausen, B. E., Dauer, M., Eigler, A., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1004114 · Cited by 112
Younes, A., Pro, B., Robertson, M. J., Flinn, I. W., Romaguera, J. E., Hagemeister, F. B., Dang, N. H., Fiumara, P. F., Loyer, E. M., Cabanillas, F., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0540 · Cited by 106
Kono, K., Mimura, K., & Kiessling, R. W. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.207 · Cited by 91
Design of chimeric antigen receptors with integrated controllable transient functions
Juillerat, A., Maréchal, A., Filhol, J.-M., Valton, J., Duclert, A., Poirot, L., & Duchateau, P. N. (2016) · Scientific Reports · doi:10.1038/srep18950 · Cited by 91
Qiao, J., Wang, H., Kottke, T. J., Díaz, R. M., Willmon, C. L., Hudacek, A. W., Thompson, J., Parato, K., Bell, J. C., Naik, J., et al. (2008) · Gene Therapy · doi:10.1038/sj.gt.3303098 · Cited by 89
Pancreatic cancer: Role of the immune system in cancer progression and vaccine-based immunotherapy
Amedei, A., Niccolai, E., & Prisco, D. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.34392 · Cited by 80
Are BiTEs the “missing link” in cancer therapy?
Suryadevara, C. M., Gedeon, P. C., Sanchez-Perez, L. A., Verla, T. G., Alvarez-Breckenridge, C. A., Choi, B. D., Fecci, P. E., & Sampson, J. H. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008339 · Cited by 75
Noguchi, M., Moriya, F., Koga, N., Matsueda, S., Sasada, T., Yamada, A., Kakuma, T., & Itoh, K. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1781-6 · Cited by 72
Personalized approaches to active immunotherapy in cancer
Ophir, E., Bobisse, S., Coukos, G., Harari, A., & Kandalaft, L. E. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.07.004 · Cited by 66
Nivolumab: Promising Survival Signal Coupled With Limited Toxicity Raises Expectations
Coyne, G. O., Madan, R. A., & Gulley, J. L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.5996 · Cited by 64
CAR-modified T-cell therapy for cancer: an updated review
Haji-Fatahaliha, M., Hosseini, M., Akbarian, A., Sadreddini, S., Jadidi‐Niaragh, F., & Yousefi, M. (2015) · Artificial Cells Nanomedicine and Biotechnology · doi:10.3109/21691401.2015.1052465 · Cited by 54
Vaccines, Adjuvants, and Dendritic Cell Activators—Current Status and Future Challenges
Obeid, J. M., Hu, Y., & Slingluff, C. L. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.006 · Cited by 50
van den Pol, A. N., & Davis, J. N. (2012) · Journal of Virology · doi:10.1128/jvi.01106-12 · Cited by 41
Alderson, R. F., Toki, B. E., Roberge, M., et al. (2006) · Bioconjugate Chemistry · doi:10.1021/bc0503521 · Cited by 40
Willemen, Y., den Bergh, J. M. J. V., Lion, E., Anguille, S., Roelandts, V. A. E., Acker, H. H. V., Heynderickx, S., Stein, B. M. H., Peeters, M., Figdor, C. G., et al. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1688-2 · Cited by 35
Cetuximab and panitumumab: are they interchangeable?
Kim, R. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70312-2 · Cited by 25
Correspondence 2: Cancer vaccines: pessimism in check
Timmerman, J. M., & Levy, R. (2004) · Nature Medicine · doi:10.1038/nm1204-1279a · Cited by 23
Pertuzumab: A New Targeted Therapy for HER 2‐Positive Metastatic Breast Cancer
Malenfant, S. J., Eckmann, K. R., & Barnett, C. M. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1338 · Cited by 23
Cited by
on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992
Maalej, K. M., Merhi, M., Inchakalody, V. P., Mestiri, S., Alam, M., Maccalli, C., Cherif, H., Uddin, S., Steinhoff, M., Marincola, F. M., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01723-z · Cited by 618
Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy
Mollica Poeta, V., Massara, M., Capucetti, A., & Bonecchi, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00379 · Cited by 583
Oncolytic virus immunotherapy: future prospects for oncology
Raja, J., Ludwig, J. M., Gettinger, S. N., Schalper, K. A., & Kim, H. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0458-z · Cited by 313
Yu, W.-D., Sun, G., Li, J., Xu, J., & Wang, X. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.02.048 · Cited by 308
Metadata
- Authors
- Papaioannou, N. E., Beniata, O. V., Vitsos, P., Tsitsilonis, O., & Samara, P.
- Venue
- Annals of Translational Medicine
- Publisher
- AME Publishing Company
- Published
- 2016-07
- Volume
- 4
- Issue
- 14
- Pages
- 261-261
- ISSN
- 2305-5839 (ISSN-L)
- 2305-5847
- OpenAlex
- W2396885039
- Cited by
- 307
- References
- 100
- FWCI
- 12.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.